Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial

Documenti analoghi

• A randomized double‐blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia
  di: Vanessa Short, et al.
  Pubblicazione: (2024)
• Donor germ‐line variants associate with outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes
  di: Paul L. Auer, et al.
  Pubblicazione: (2024)
• Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study
  di: Masataka Kuwana, et al.
  Pubblicazione: (2024)
• Correction to “Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies”
  Pubblicazione: (2024)
• Circadian Deregulation in Multiple Myeloma: BMAL1 / CLOCK Expression Patterns and Diagnostic Performance
  di: Hamide Albayrak, et al.
  Pubblicazione: (2026)